gutflix
GI learning, personalised

Summary

ANTI–IL-13 (CENDAKIMAB) ADMINISTRATION IMPROVES OESOPHAGEAL GENE EXPRESSION IN EOSINOPHILIC OESOPHAGITIS

Marc E. Rothenberg

UEG Week Copenhagen 2023 | Poster

Oesophagus

October 17, 2023

Cendakimab, an anti-IL-13 monoclonal antibody, reversed gene expression profiles of key pathways in eosinophilic oesophagitis in a phase 2 trial substudy.

KEY POINTS

- Cendakimab at 180 mg or 360 mg doses administered over 16 weeks reversed gene expression in IL-13 signalling, mastocytosis, epithelial differentiation, and remodelling pathways compared with placebo
- CCL26 showed 16-fold decreases with both doses, CPA3 decreased 4.1-fold and 4.7-fold, POSTN decreased 16-fold with both doses, and DSG1 increased 12.3-fold and 6.7-fold with 180 mg and 360 mg respectively
- Transcript changes correlated with histological and endoscopic observations
- Patients achieving histological remission showed significantly greater improvement in expression of 8 genes including CCL26 and CPA3 compared with non-responders
- This substudy of a double-blind placebo-controlled phase 2 trial quantified EoE-related transcripts in oesophageal biopsies at baseline and week 16

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/6f783f20-743b-11ee-b442-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.